Taking the Road Less Traveled: Following Molecular Trail Markers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35960159.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1623.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies. See related article by Manning-Geist et al., p. 4456.
Medical subject headings
- Cystadenocarcinoma, Serous
- Ovarian Neoplasms
- Peritoneal Neoplasms